Loading stock data…
PRE
$17.02+0.31 (+1.86%)
Market ClosedLast close May 1
Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prenetics Global Limited in the Healthcare sector is trading at $17.02. The stock is currently 28% below its 52-week high of $23.63, remaining 15.7% above its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why PRE maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$17.02
Potential Upside
5%
Whystock Fair Value$17.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$309.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.86%
Volume
Today's trading volume
150,543
Recent News
Top Growth Companies With Insider Stakes In April 2026
In the last week, the United States market has stayed flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often reflect management's confidence in their business prospects and alignment with shareholder interests.
Pensana banks $15m tranche from Cascade as it advances Longonjo rare earth project
Pensana PLC (LSE:PRE, OTC:PNSPF) has received the first US$15 million tranche of a US$165 million strategic investment from Cascade Natural Resources, giving the rare earths developer fresh capital to push ahead with its US mine-to-magnet strategy and the Longonjo project in Angola. The...
Prenetics Global (PRE) Partners with Superpower on Diagnostics and Supplements
Prenetics Global Limited (NASDAQ:PRE) is one of the 7 Fastest Growing Asian Stocks to Buy. On March 24, 2026, Prenetics Global Limited (NASDAQ:PRE) announced a strategic partnership with Superpower to combine clinical-grade supplementation with blood diagnostics. The company said the collaboration integrates testing and supplementation into a unified system, allowing consumers to measure supplement effectiveness, […]
Prenetics Global Conference: CEO Danny Yeung details IM8’s $100M ARR surge with David Beckham
A panel at an RX3 event in Orange County brought together leaders from wellness, supplements, and beverages to discuss how they work with influencers and celebrities—and why authenticity and product performance remain central to their strategies. Executives outline brand backgrounds and growth path
Prenetics Global Conference: CEO Pivots to IM8, Targets $200M 2026 Sales and $40M Buyback
Prenetics Global (NASDAQ:PRE) co-founder and CEO Danny Yeung said the company is now centered on its IM8 supplement business after divesting non-core operations over the past 12 to 18 months, pointing to rapid early growth since IM8’s launch in December 2024. Positioning IM8 in a competitive market